UTHR
UNITED THERAPEUTICS Corp
$563.70
+16.45 (+3.01%)
At close · Jul 7
Market Cap
$23.93B
Shares
42,446,733
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$3.18B
+10.6%
FY2025
Net Income
$1.33B
+11.7%
FY2025
Gross Margin
87.92%
-1.3pp
FY2025
Operating Margin
46.89%
-1pp
FY2025
Diluted EPS
$27.86
+13.1%
FY2025
Operating Cash Flow
$1.56B
+17.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.17B | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B | $1.48B | $1.45B | $1.63B | $1.73B | $1.6B | $1.47B | $1.29B | $1.12B | $916.08M | $743.18M | $603.83M | |
| $425.3M | $384.4M | $309.7M | $257.5M | $151.6M | $122.5M | $108.1M | $117.6M | $198.7M | $105.7M | $72.7M | $69.04M | $125.88M | $131.13M | $119.3M | $88.9M | $67.72M | |
| $2.74B | $2.8B | $2.57B | $2.07B | $1.78B | $1.56B | — | $282.3M | $349.5M | $411.7M | $380.6M | $379.57M | $1.15B | $975.82M | $786.83M | $652.19M | — | |
| — | 87.92% | 89.24% | 88.94% | 92.17% | 92.73% | — | 19.49% | 21.47% | 23.86% | 23.81% | 25.9% | 89.53% | 87.36% | 85.89% | 87.76% | — | |
| $539.2M | $550M | $481M | $408M | $322.9M | $540.1M | $357.7M | $1.18B | $357.9M | $264.6M | $147.6M | $245.1M | $242.55M | $299.35M | $173.39M | $180.02M | $166.76M | |
| $769.8M | $755.8M | $709.7M | $477.1M | — | — | — | — | $265.8M | $330.1M | $316.8M | $452.61M | $381.29M | $394.01M | $201.75M | $156.48M | $199.6M | |
| — | $900K | $900K | $300K | $100K | $100K | $200K | $200K | $100K | $500K | $600K | $1.1M | $1.4M | $2.6M | $2.1M | — | — | |
| — | $85.6M | $72.5M | $53.2M | $51.3M | $49.9M | $49.9M | $45.9M | $35.9M | $31M | $31.6M | $32.92M | $32.25M | $31.26M | $27.15M | $20.54M | $17.92M | |
| $1.73B | $1.69B | $1.5B | $1.14B | $956.6M | $1.13B | $889.7M | $1.64B | $822.4M | $910.4M | $537.1M | $766.75M | $749.72M | $824.49M | $494.43M | $425.4M | $439.83M | |
| $1.44B | $1.49B | $1.38B | $1.18B | $979.7M | $555.9M | $593.6M | -$187.6M | $805.4M | $814.9M | $1.06B | $699.02M | $538.8M | $292.5M | $421.65M | $317.78M | $164.01M | |
| — | 46.89% | 47.86% | 50.91% | 50.6% | 32.98% | 40.02% | -12.95% | 49.48% | 47.23% | 66.41% | 47.69% | 41.82% | 26.19% | 46.03% | 42.76% | 27.16% | |
| — | $1.58B | $1.45B | $1.24B | $1.03B | $605.8M | $643.5M | -$141.7M | $841.3M | $845.9M | $1.09B | $731.94M | $571.05M | $323.76M | $448.79M | $338.32M | $181.93M | |
| $16.4M | $19.5M | $42.9M | $59.3M | $32.4M | $18.6M | $23.5M | $44.2M | $13.9M | $9M | $3.9M | $4.74M | $17.59M | $18.06M | $16.64M | $21.37M | $19.71M | |
| $182.7M | $192M | $199.1M | $162.7M | $45.2M | $16.7M | $28.6M | $44.2M | $28.6M | — | — | — | — | $3.83M | $3.94M | $3.45M | $2.94M | |
| $173.2M | $221.4M | $162M | $89.4M | -$29.1M | $38M | $45.3M | $22.6M | -$46.5M | -$45.4M | -$1.5M | $345.42M | -$13.62M | -$13.6M | $19.03M | -$18.67M | -$16.17M | |
| -$200K | — | — | — | — | — | — | — | — | — | — | — | — | — | -$143K | -$119K | -$160K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$7.69M | |
| $1.61B | $1.71B | $1.54B | $1.27B | $950.6M | $593.9M | $638.9M | -$165M | $758.9M | $769.5M | $1.06B | $1.04B | $525.18M | $278.9M | $440.67M | $299.12M | — | |
| $321.3M | $379.2M | $343.9M | $289.5M | $223.3M | $118.1M | $124.1M | -$60.5M | $169.7M | $351.6M | $346.5M | $392.8M | $185.11M | $104.34M | $136.23M | $81.87M | $41.92M | |
| $1.29B | $1.33B | $1.2B | $984.8M | — | — | — | -$104.5M | $589.2M | $417.9M | — | — | — | — | — | — | $105.92M | |
| — | 41.94% | 41.53% | 42.31% | — | — | — | -7.21% | 36.2% | 24.22% | — | — | — | — | — | — | 17.54% | |
| — | — | — | — | $727.3M | $475.8M | $514.8M | -$104.5M | $589.2M | $417.9M | $713.7M | $651.64M | $340.07M | $174.56M | $304.44M | $217.87M | — | |
| $1.28B | $1.34B | $1.2B | $1.03B | $694.8M | $467M | $514.8M | -$110.8M | $600.9M | $415.1M | $717.3M | $647.97M | $336.52M | $176.33M | $300.37M | $216.16M | — | |
| USD/shares | — | $30.13 | $26.44 | $21.04 | $15.98 | $10.60 | $11.65 | -$2.39 | $13.54 | $9.50 | $16.29 | $14.17 | $7.06 | $3.49 | $5.84 | $3.81 | $1.89 |
| USD/shares | — | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 | $11.54 | -$2.39 | $13.39 | $9.31 | $15.25 | $12.72 | $6.28 | $3.28 | $5.71 | $3.67 | $1.78 |
| shares | — | 44.3M | 45.2M | 46.8M | 45.5M | 44.9M | 44.2M | 43.8M | 43.5M | 44M | 43.8M | 46M | 48.18M | 50.08M | 52.09M | 57.16M | 56.14M |
| shares | — | 47.9M | 48.5M | 49.7M | 48.5M | 47.3M | 44.6M | 43.8M | 44M | 44.9M | 46.8M | 51.22M | 54.16M | 53.23M | 53.28M | 59.4M | 59.52M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2025: $4.57B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
20.84×
Drug Manufacturers - Specialty & Generic median 21.31×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $3,037,000,000 | $2,739,700,000 | $2,202,200,000 | $1,814,100,000 | $1,564,200,000 | $1,412,100,000 | $1,323,200,000 | $1,528,200,000 |
| Non Us | $145,700,000 | $137,700,000 | $125,300,000 | $122,200,000 | $121,300,000 | $71,200,000 | $125,600,000 | — |
| European Union And Others | — | — | — | — | — | — | — | $99,600,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Tyvaso | $1,878,200,000 | $1,620,400,000 | $1,233,700,000 | $873,000,000 | $607,500,000 | $483,300,000 | $415,600,000 | $415,200,000 |
| TyvasoDPI | $1,292,500,000 | $1,033,600,000 | $731,100,000 | $158,300,000 | $0 | — | — | — |
| Nebulized Tyvaso | $585,700,000 | $586,800,000 | $502,600,000 | $714,700,000 | $607,500,000 | — | — | — |
| Remodulin | $526,800,000 | $538,100,000 | $494,800,000 | $500,200,000 | $513,700,000 | $516,700,000 | $587,000,000 | $599,000,000 |
| Orenitram | $496,900,000 | $434,300,000 | $359,400,000 | $325,100,000 | $306,100,000 | $293,100,000 | $225,300,000 | $205,100,000 |
| Unituxin | $226,800,000 | $238,700,000 | $198,900,000 | $182,900,000 | $202,300,000 | $122,900,000 | $113,700,000 | $84,800,000 |
| Adcirca | $30,000,000 | $23,800,000 | $28,900,000 | $41,300,000 | $55,900,000 | $67,300,000 | $107,200,000 | $323,700,000 |
| Product And Service Other | $24,000,000 | $22,100,000 | $11,800,000 | $13,800,000 | $0 | $0 | — | — |
Key facts
CIK
1082554
CUSIP
91307C102
13F (30d)
51 filings
28 filers
Visit website
Investor relations